127 related articles for article (PubMed ID: 32882127)
1. Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB
Sun Y; Ke Y; Li C; Wang J; Tu L; Hu L; Jin Y; Chen H; Gong J; Yu Z
J Med Chem; 2020 Oct; 63(19):10816-10828. PubMed ID: 32882127
[TBL] [Abstract][Full Text] [Related]
2. Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.
Shin HC; Kim JS; Vig BS; Song X; Drach JC; Amidon GL
Biol Pharm Bull; 2006 Feb; 29(2):247-52. PubMed ID: 16462026
[TBL] [Abstract][Full Text] [Related]
3. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis.
Vig BS; Lorenzi PJ; Mittal S; Landowski CP; Shin HC; Mosberg HI; Hilfinger JM; Amidon GL
Pharm Res; 2003 Sep; 20(9):1381-8. PubMed ID: 14567631
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.
Tsume Y; Hilfinger JM; Amidon GL
Mol Pharm; 2008; 5(5):717-27. PubMed ID: 18652477
[TBL] [Abstract][Full Text] [Related]
5. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.
Landowski CP; Song X; Lorenzi PL; Hilfinger JM; Amidon GL
Pharm Res; 2005 Sep; 22(9):1510-8. PubMed ID: 16132363
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs.
Landowski CP; Vig BS; Song X; Amidon GL
Mol Cancer Ther; 2005 Apr; 4(4):659-67. PubMed ID: 15827340
[TBL] [Abstract][Full Text] [Related]
7. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters.
Tsume Y; Vig BS; Sun J; Landowski CP; Hilfinger JM; Ramachandran C; Amidon GL
Molecules; 2008 Jun; 13(7):1441-54. PubMed ID: 18719516
[TBL] [Abstract][Full Text] [Related]
8. Controlled release of 3',5'-diester prodrugs of 5-fluoro-2'-deoxyuridine from poly-L-lactic acid microspheres.
Seki T; Kawaguchi T; Endoh H; Ishikawa K; Juni K; Nakano M
J Pharm Sci; 1990 Nov; 79(11):985-7. PubMed ID: 2149864
[TBL] [Abstract][Full Text] [Related]
9. ATB
Lou D; Lou Z; Lin Y; Shangguan H; Lin Y; Luo Q; Zhang H; Lin G; Chen R; Kou L; Bao S
Bioorg Med Chem Lett; 2021 Feb; 33():127728. PubMed ID: 33346010
[TBL] [Abstract][Full Text] [Related]
10. 5'-[2-(2-Nitrophenyl)-2-methylpropionyl]-2'-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: synthesis, stability and reductive activation.
Hu L; Liu B; Hacking DR
Bioorg Med Chem Lett; 2000 Apr; 10(8):797-800. PubMed ID: 10782689
[TBL] [Abstract][Full Text] [Related]
11. The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.
Tsume Y; Amidon GL
Molecules; 2012 Mar; 17(4):3672-89. PubMed ID: 22450679
[TBL] [Abstract][Full Text] [Related]
12. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
Jiang H; Lu J; Jiang J; Hu P
J Clin Pharmacol; 2004 Nov; 44(11):1260-72. PubMed ID: 15496644
[TBL] [Abstract][Full Text] [Related]
13. Controlled release of 5-fluoro-2'-deoxyuridine by the combination of prodrug and polymer matrix.
Endoh H; Kawaguchi T; Seki T; Hasegawa T; Juni K
Chem Pharm Bull (Tokyo); 1991 Feb; 39(2):458-64. PubMed ID: 1829027
[TBL] [Abstract][Full Text] [Related]
14. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Tsume Y; Drelich AJ; Smith DE; Amidon GL
Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs.
Wu W; Borch RF
Mol Pharm; 2006; 3(4):451-6. PubMed ID: 16889439
[TBL] [Abstract][Full Text] [Related]
16. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
18. Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.
Tsume Y; Hilfinger JM; Amidon GL
Pharm Res; 2011 Oct; 28(10):2575-88. PubMed ID: 21671137
[TBL] [Abstract][Full Text] [Related]
19. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.
Kim I; Song X; Vig BS; Mittal S; Shin HC; Lorenzi PJ; Amidon GL
Mol Pharm; 2004; 1(2):117-27. PubMed ID: 15832508
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver.
Vivian D; Polli JE
Int J Pharm; 2014 Nov; 475(1-2):597-604. PubMed ID: 25219859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
